Dyadic International Inc.

Biotechnology • Healthcare • Jupiter, FL, United States • DYAI (NCM)

561 743 8333 1044 North U.S. Highway One, Jupiter, FL 33477-5094, United States

Quarter: Q3 2025 Reported: August 13, 2025 Sentiment: Neutral

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Analysis Summary

This filing from Dyadic International Inc. (DYAI) confirms the announcement of its Q3 2025 financial results on August 13, 2025, for the period ending June 30, 2025. The core financial data, including revenue, net income, EPS, and any forward-looking guidance, are not presented within this document but are referenced as being available in Exhibit 99.1 of the accompanying Form 8-K. Therefore, a detailed breakdown of financial performance, strategic initiatives, business segment analysis, management commentary, competitive positioning, market trends, or specific risk factors cannot be derived from the provided text. The document primarily serves as a procedural notification regarding the release of results, directing interested parties to the full press release for actual performance metrics and operational insights. No analyst Q&A highlights or specific confidence/risk indicators can be identified from this limited information.

Key Highlights

• Q3 2025 results announced on August 13, 2025.
• Results pertain to the quarter ended June 30, 2025.
• Full financial and operational details are contained in the referenced press release (Exhibit 99.1).
• The information in this report is furnished and not deemed 'filed' for Section 18 of the Exchange Act.
• Such information is not incorporated by reference in other filings without specific mention.
• This filing is a procedural notification of results release.
• Specific financial and operational data are not included in this document.

Financial Metrics

eps

N/A

YoY: N/A

revenue

N/A N/A

YoY: N/A

guidance

net income

N/A N/A

YoY: N/A

Stock Performance (90 Days)

Data through Dec 26, 2025

Layoff Events

Earnings Calls

Positive Signals

• Company is adhering to regulatory reporting requirements.
• Q3 2025 results were officially announced.
• A detailed press release (Exhibit 99.1) is available for comprehensive review.